DUAVEE (conjugated estrogens/bazedoxifene) by Pfizer is estrogen receptor agonists [moa]. First approved in 2013.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
DUAVEE is an oral combination therapy combining conjugated estrogens with bazedoxifene, a selective estrogen receptor modulator (SERM). It is indicated for moderate to severe vasomotor symptoms associated with menopause and for prevention of postmenopausal osteoporosis. The drug works by activating estrogen receptors to address menopausal symptoms while the SERM component provides bone protection with a potentially improved safety profile compared to estrogen monotherapy.
With LOE imminent (0.7 years remaining), the commercial team is likely focused on maximizing remaining revenue and managing the transition to generic competition rather than growth initiatives.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The PROMISE Study: Duavee in Women With DCIS
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
Worked on DUAVEE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on DUAVEE offers limited long-term career development given the imminent loss of exclusivity and minimal linked job openings. This role is best suited for professionals seeking to execute a managed decline strategy, optimize final years of revenue, and prepare for transition to other products within Pfizer's women's health portfolio.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo